Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isla S Mackenzie

Showing results (71-80 of 90) with videos related to

Pageof 9
Sort By:
Eclinicalmedicine|May 22, 2024
Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) studyFilippo Pigazzani, Kenneth A Dyar, Steve V Morant, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 2002
Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial functionIan B Wilkinson, Ian R Hall, Helen MacCallum, et al.
European Heart Journal Open|December 11, 2024
Vascular and inflammatory biomarkers of cardiovascular events in non-steroidal anti-inflammatory drug usersRicky Vaja, Plinio Ferreira, Laura Portas, et al.
The Lancet. Diabetes & Endocrinology|October 23, 2015
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trialMorris J Brown, Bryan Williams, Steve V Morant, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2018
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudiesBryan Williams, Thomas M MacDonald, Steve V Morant, et al.
BMJ Open|July 12, 2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaThomas M MacDonald, Ian Ford, George Nuki, et al.
Journal of the American Heart Association|November 20, 2017
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled TrialThomas M MacDonald, Bryan Williams, David J Webb, et al.
Lancet (London, England)|November 12, 2020
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trialIsla S Mackenzie, Ian Ford, George Nuki, et al.
Hypertension (Dallas, Tex. : 1979)|July 30, 2024
<i>UMOD</i> Genotype-Blinded Trial of Ambulatory Blood Pressure Response to TorasemideLinsay McCallum, Stefanie Lip, Alex McConnachie, et al.
Clinical Pharmacology and Therapeutics|September 1, 2025
Bringing Trial Activities to Participants-The Trials@Home RADIAL Proof-of-Concept Trial Investigating Decentralization of TrialsMira G P Zuidgeest, Megan Heath, Bart Lagerwaard, et al.
Pageof 9

Showing results (71-80 of 90) with videos related to

Sort By:
Pageof 9
Eclinicalmedicine|May 22, 2024
Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) studyFilippo Pigazzani, Kenneth A Dyar, Steve V Morant, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|January 15, 2002
Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial functionIan B Wilkinson, Ian R Hall, Helen MacCallum, et al.
European Heart Journal Open|December 11, 2024
Vascular and inflammatory biomarkers of cardiovascular events in non-steroidal anti-inflammatory drug usersRicky Vaja, Plinio Ferreira, Laura Portas, et al.
The Lancet. Diabetes & Endocrinology|October 23, 2015
Effect of amiloride, or amiloride plus hydrochlorothiazide, versus hydrochlorothiazide on glucose tolerance and blood pressure (PATHWAY-3): a parallel-group, double-blind randomised phase 4 trialMorris J Brown, Bryan Williams, Steve V Morant, et al.
The Lancet. Diabetes & Endocrinology|April 16, 2018
Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PATHWAY-2 mechanisms substudiesBryan Williams, Thomas M MacDonald, Steve V Morant, et al.
BMJ Open|July 12, 2014
Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemiaThomas M MacDonald, Ian Ford, George Nuki, et al.
Journal of the American Heart Association|November 20, 2017
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled TrialThomas M MacDonald, Bryan Williams, David J Webb, et al.
Lancet (London, England)|November 12, 2020
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trialIsla S Mackenzie, Ian Ford, George Nuki, et al.
Hypertension (Dallas, Tex. : 1979)|July 30, 2024
<i>UMOD</i> Genotype-Blinded Trial of Ambulatory Blood Pressure Response to TorasemideLinsay McCallum, Stefanie Lip, Alex McConnachie, et al.
Clinical Pharmacology and Therapeutics|September 1, 2025
Bringing Trial Activities to Participants-The Trials@Home RADIAL Proof-of-Concept Trial Investigating Decentralization of TrialsMira G P Zuidgeest, Megan Heath, Bart Lagerwaard, et al.
Pageof 9